Summary: Tongliao Meihua plans to introduce 6,500 t/a of production capacity for isoleucine.
On
22 March, the environmental impact (EI) report of isoleucine project
from Tongliao Meihua Biological Sci-tech Co., Ltd. (Tongliao Meihua) was
published.
Project overview
Type of project: reconstruction and expansion
Investment
amount: USD3.80 million (RMB27.00 million), 4.81% of which
(USD182,946/RMB1.30 million) will be for environmental protection
purposes
Construction site location: Horqin District, Tongliao City, Inner Mongolia Autonomous Region
Site area: 4,988 square metres
Construction
details: In the existing tryptophan production workshop, the tryptophan
line will be dismantled, and a new isoleucine line will be built.
Planned capacities: 6,450 t/a for feed-grade isoleucine and 50 t/a for food-grade isoleucine
Major raw materials needed in production: 5,854 t/a of glucose and 3,089 t/a of beet molasses
Production
process: The microbial anaerobic fermentation method is first applied
to produce fermentation broth. Then, fermentation broth undergoes
filtration by ceramic membrane, decolourisation by activated carbon,
multiple-effect evaporation, crystallisation, separation and drying. In
the end, isoleucine is produced.
Labour
needs & working schedule: There won't be new job posts created for
this project. There will be 333 working days/7,992 working hours per
year.
Economic benefits:
Estimations show the project will bring in yearly operating revenues of
USD54.88 million (RMB390.00 million) and yearly after-tax profits of
USD20.94 million (RMB148.77 million) after it reaches full operation.
Tongliao
Meihua's operating revenue for 2023 totalled USD1.41 billion (RMB10.02
billion) and net profit for 2023 was USD142.14 million (RMB1.01
billion), according to the performance report of its parent Meihua
Holdings Group Co., Ltd. (stock code: 600873.SH). Tongliao Meihua's
production capacities for amino acids, including the operational ones
and the ones to be built, are summarised in the following table.
Table Tongliao Meihua's production capacities for amino acids in its factory compound
|
Product
|
Production capacity, t/a
|
Note
|
|
Gourmet powder monosodium glutamate
|
200,000
|
In operation
|
|
500,000
|
To be built; related project has been filed for record
|
|
Tryptophan
|
10,000
|
In operation; to be removed in order to make way for isoleucine project
|
|
Glutamine
|
5,000
|
In operation
|
|
Valine
|
21,800
|
|
Threonine
|
250,000
|
|
Isoleucine
|
6,500
|
To be built by isoleucine project
|
Source: Tongliao Meihua
Source:CCM
More information can be found at CCM Amino acid China Monthly Report.
About CCM:
CCM is the leading market intelligence provider for China’s agriculture, chemicals, food &
feed and life science markets. Founded in 2001, CCM offers a range of
content solutions, from price and trade analysis to industry newsletters
and customized market research reports. CCM is a brand of Kcomber Inc.
For
more information about CCM, please visit www.cnchemicals.com or get in
touch with us directly by emailing econtact@cnchemicals.com or calling
+86-20-37616606.